Preprint
Review

This version is not peer-reviewed.

Developing Evidence-Based Micronutrient Guidelines: An Integrative Orthomolecular Systems Medicine Framework

Submitted:

21 October 2026

Posted:

22 October 2026

You are already at the latest version

Abstract
Background: Dietary reference values and many supplementation studies focus on preventing deficiency, maintaining nutritional adequacy, or avoiding excessive exposure. These are essential objectives but do not settle whether altered nutrient requirements, clinically meaningful insufficiency, or distinct pharmacological interventions warrant investigation. Nutrient trials also differ from many drug trials because all participants have pre-existing nutrient exposure and effects can depend on baseline status, achieved concentrations, and biological timing.Objective: To propose a transparent, biologically informed methodology for developing and evaluating micronutrient guidelines across nutritional and therapeutic applications without weakening standards for causal claims, clinical benefit, or safety.Methods: We present a critical narrative synthesis of nutrient-specific trial methodology, dietary reference intakes, toxicology, selected trials, and guideline-development standards. We trace antecedents from Cheng’s 2024 discussion of nutritional versus therapeutic dosing, Grant et al.’s 2025 vitamin D guideline review, and Cheng’s 2026 Nutrient Prioritization preprint; the present framework integrates prior principles and articulates two additional proposed principles [17–19].Framework: The Integrative Orthomolecular Systems Medicine Micronutrient Guideline Development Framework (I-OM-MGDF) integrates the previously described Nutrient Demand and Nutrient Prioritization concepts with two principles newly named and formulated here: Nutrient Safety–Benefit Exploration and the Nutrient Functional–Therapeutic Continuum. Fourteen assessment domains connect physiology, dose, harms, evidence certainty, and recommendation development.Conclusions: Micronutrient guidelines should explicitly separate deficiency prevention, correction of evidence-supported insufficiency, physiological optimization hypotheses, and disease-specific pharmacological treatment. An intake below an identified toxicity threshold is not automatically safe or beneficial, but a biologically plausible, ethically justified exposure can merit rigorous study. Clinical recommendations should target demonstrated net benefit rather than the highest tolerated dose. The I-OM-MGDF is a proposal for subsequent pilot testing, expert appraisal, and validation—not an endorsed or validated practice guideline.
Keywords: 
;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  

1. Introduction

Essential vitamins and minerals support human development, metabolic regulation, enzymatic activity, tissue maintenance, and repair. Nutrient recommendations must therefore account for biological necessity. Yet the scientific questions surrounding essentiality, population adequacy, prevention of a specified disease, and treatment of established disease are not interchangeable. A nutrient can be indispensable for life and nevertheless show no incremental benefit—or cause harm—when administered in excess to a nutritionally replete population.
A conventional drug trial often contrasts receipt of an investigational intervention with its absence. By contrast, the control group of a micronutrient trial usually receives the nutrient through food, fortification, supplements, or endogenous stores. The biological contrast is additional exposure against existing exposure. Nutrient responses may also vary along a nonlinear exposure–response curve: correcting deficiency may yield a large effect, whereas supplementing beyond adequate status may yield little additional benefit or adverse effects. Heaney emphasized the importance of baseline status, trial dose, and achieved change when designing nutrient studies [1,2].
Established Dietary Reference Intakes (DRIs), including Estimated Average Requirements (EARs), Recommended Dietary Allowances (RDAs), Adequate Intakes (AIs), and Tolerable Upper Intake Levels (ULs), serve defined nutritional assessment and planning purposes [3]. An RDA is neither a universal optimum for every medical condition nor evidence that doses above it are helpful. Similarly, a UL is a population risk-management reference, not a validated maximum therapeutic dose. Clinical guideline developers need to identify precisely which question is being answered.

1.1. Intellectual Antecedents and Specific Novelty

Cheng’s 2024 Orthomolecular Medicine News Service article contrasted conventional nutrition reference intakes with individualized and potentially pharmacological nutrient dosing, highlighting safety and oversight considerations [17]. Grant, Wimalawansa, Pludowski, and Cheng (2025) critically examined vitamin D population guideline development and differing interpretations of clinical and observational evidence [18]. These publications provide antecedents for the current methodology; their contested conclusions should not be mistaken for scientific consensus.
Cheng’s June 2026 preprint explicitly proposed the Nutrient Prioritization Principle and Nutrient Dependency Framework, including a four-level hierarchy—foundational nutrition, increased-demand nutrients, therapeutic interventions, and optimization or longevity strategies—and identified an increased-demand concept as the Nutrient Demand Principle [19]. The present article therefore does not claim that Nutrient Demand or Nutrient Prioritization is introduced for the first time. Rather, it adapts them for guideline development and newly formulates the Safety–Benefit Exploration and Functional–Therapeutic Continuum Principles as named constructs, without claiming that every underlying biological concept is novel.
This article proposes a framework for developing guidelines about micronutrients, rather than a set of recommended doses for particular patients. It aims to improve the completeness of guideline questions, not to supplant evidence appraisal. The four I-OM principles are presented as author-proposed organizing constructs; they should not be described as independently validated doctrines or consensus standards.

2. Review Approach and Scope

This is a narrative methodological review. Foundational sources were selected from nutritional requirements, nutrient-trial methodology, toxicological evaluation, clinical trial literature, and evidence-to-decision guidance. The illustrative examples are not an exhaustive review, and conclusions about effectiveness are limited to the cited outcomes and populations. No formal search strategy, eligibility screening, bias assessment across all available studies, registered protocol, or meta-analysis was undertaken. Thus the article does not estimate pooled treatment effects or claim completeness of the evidence base.
The intended users of the proposed I-OM-MGDF are investigators designing nutrient studies, systematic reviewers synthesizing those studies, and guideline panels seeking to ensure that nutrient-specific questions are systematically addressed before recommendations are formulated.

3. Four Proposed I-OM Principles

3.1. Nutrient Demand Principle (NDP)

Definition: Nutrient requirements and relevant biological exposure may vary with life stage, physiological state, illness, absorption, metabolism, medication exposure, and nutrient loss. A reference intake derived for a healthy population should not be presumed sufficient—or insufficient—for every clinical scenario. The increased-demand concept was described in Cheng’s prior prioritization framework [19]; here it is converted into an explicit guideline appraisal domain.
Operational questions are whether the target population has an established difference in intake requirements; whether validated biomarkers indicate inadequate status or utilization; whether the proposed additional intake changes the relevant physiological variable; and whether doing so improves clinical outcomes. Pregnancy, malabsorption, and selected deficiency disorders offer examples of established context-dependent needs. By contrast, a nonspecific assumption that all inflammation, metabolic stress, or environmental exposure warrants higher supplementation is a hypothesis requiring testing.
The NDP is therefore a rule to evaluate changes in demand, not a rule to prescribe higher doses. It can justify both enrichment of trials with high-risk populations and restraint when increased requirements are unproven.

3.2. Nutrient Prioritization Principle (NPP)

Definition: Nutritional issues and interventions should be prioritized according to clinical urgency, established deficiency, biological importance, anticipated patient-important benefit, evidentiary certainty, safety, and feasibility. Foundational sufficiency often deserves attention before speculative optimization, without making this a rigid treatment sequence. This builds directly on Cheng’s previously published four-tier Nutrient Prioritization Principle [19]; the guideline version adds urgency, evidence certainty, and implementation considerations.
Ames’s triage theory hypothesizes that limited micronutrient availability may preserve short-term survival functions at the expense of longer-term maintenance functions [4]. It motivates relevant research questions but does not by itself demonstrate that escalating every nutrient intake reduces chronic disease. Operational prioritization should account for the consequences of delaying intervention, the strength of supporting evidence, cost, and patient preference. In urgent clinical care, an evidence-based disease-specific treatment may reasonably take precedence over broad nutritional optimization.

3.3. Nutrient Safety–Benefit Exploration Principle (NSBEP)

Definition: The entire scientifically relevant exposure range should be considered for potential benefits and harms, with prespecified safety boundaries and appropriate study designs. Investigation should not stop automatically at the intake required to prevent classical deficiency, nor proceed automatically toward a maximum tolerated dose. The specific named principle is proposed in the present work, building on earlier arguments about therapeutic doses and safety supervision [17].
This principle poses a testable question: when benefits at exposures beyond conventional adequacy are biologically plausible, is the evidence and expected risk profile sufficient to justify further study? An affirmative answer supports carefully designed research, not routine prescription. Non-observation of adverse events in a small or short study cannot establish safety against rare, delayed, cumulative, formulation-specific, or susceptible-population harms.
For each candidate exposure, risk evaluation should characterize the dose and chemical form; dietary plus supplemental exposure; route; duration and accumulation; severity and frequency of adverse effects; reversibility; interaction risks; and vulnerable groups. Mild, moderate, severe, and life-threatening outcomes can be described using recognized adverse-event frameworks, rather than a newly invented universal toxicity grading scale.
The UL, a maximum tolerated dose (MTD), and a clinically optimal therapeutic regimen are different constructs. ULs are generally derived for sustained intake in broad populations; therapeutic dosing may be investigated outside these limits under conditions of sufficient justification and safeguards. An MTD establishes tolerability in a defined study, not superior efficacy. The appropriate therapeutic aim is the most favorable demonstrated net clinical benefit, not the highest dose without immediate symptoms.
Vitamin B6 is a cautionary illustration. The European Food Safety Authority established an adult UL of 12 mg/day in 2023 after considering peripheral neuropathy and uncertainties relating to dose and duration [5]. The US system reports a different adult UL; such variation underscores that safety thresholds depend on evidence appraisal and policy assumptions, not a unique biological cliff. It would be incorrect to infer that any dose just below one authority’s UL is guaranteed safe for every individual.

3.4. Nutrient Functional–Therapeutic Continuum Principle (NFTCP)

Definition: Micronutrient interventions should be classified by their intended claim: (i) preventing overt deficiency; (ii) correcting established inadequacy or insufficiency; (iii) investigating improvements in validated physiological functions beyond conventional adequacy; (iv) preventing or treating a specified clinical condition; or (v) producing pharmacological effects through exposures, forms, or routes that differ substantially from ordinary dietary exposure. The named continuum principle is articulated here; related distinctions between adequacy and therapeutic use appeared in prior publications [17,19].
These are categories of intended use rather than progressively superior dose levels. Definitions of “insufficiency” and “optimal” vary between nutrients. A laboratory target should not be labeled optimal without evidence linking achievement of that target to meaningful benefit. Likewise, physiological or cellular effects at pharmacological concentrations do not establish improvements in survival, symptoms, function, or quality of life.
Vitamin C illustrates the continuum. Physiological replacement prevents and treats scurvy. Oral intake beyond requirements can be evaluated against specific clinical outcomes. High-dose intravenous administration achieves substantially greater plasma exposure than oral dosing and is pharmacokinetically a different intervention [6]. Therefore studies of oral vitamin C do not automatically test intravenous pharmacological regimens. Conversely, distinct pharmacokinetics do not establish disease-specific efficacy.

4. Methodological Distinctions from Conventional Pharmaceutical Trials

Nutrient-specific trial design requires attention to: unavoidable control-group exposure; baseline intake and nutritional state; biologically relevant dose selection; nonlinear and potentially U-shaped responses; achieved exposure, adherence, and bioavailability; co-nutrient and dietary interactions; timing relative to a developmental or disease window; sufficient follow-up for the primary endpoint; precise clinical target definition; and balanced interpretation of null and adverse results [1,2,7]. These considerations supplement rather than replace randomization, allocation concealment, masking, preregistration, intention-to-treat analysis, statistical precision, and adverse-event reporting.
A negative trial provides evidence about the intervention tested, in the population observed, for the specified endpoints. A deficiency-correction benefit may not be generalizable from a trial that primarily enrolls replete individuals. Nonetheless, claims that a negative result reflects the wrong population, dose, or route should be prespecified or independently corroborated; otherwise they risk becoming unfalsifiable explanations for lack of effect. Positive trials deserve the same scrutiny.
Biomarker measurement is useful but not inherently decisive. Serum concentrations may be influenced by inflammation, organ function, binding proteins, timing, and assay differences. Achieved nutrient concentration is a post-randomization variable and comparisons among participants who happen to achieve a specific concentration may be confounded. The randomized comparison should generally remain primary, with prespecified biomarker and interaction analyses providing supporting information.

5. The Fourteen-Domain I-OM Micronutrient Guideline Development Checklist

Domain Focus Required question
1 Physiological essentiality What functions and deficiency syndromes are established?
2 Baseline exposure and status What intake, fortification, supplements, stores, and validated biomarkers characterize the population?
3 Nutrient demand Which contexts demonstrably or plausibly change requirements?
4 Nutrient prioritization Which abnormalities or interventions matter most clinically?
5 Insufficiency definition Is insufficient status validated or merely hypothesized?
6 Intended use classification Adequacy, insufficiency correction, optimization, disease treatment, or pharmacological use?
7 Dose, route, and exposure Are formulation, bioavailability, kinetics, achieved concentrations, and total exposure adequate to test the question?
8 Biological interactions Do co-nutrients, diet, disease, or medication meaningfully modify response?
9 Timing and follow-up Is the biological intervention window and outcome latency respected?
10 Clinical benefits Are patient-important outcomes improved, and with what precision?
11 Graded toxicity What adverse effects occur at what exposure, severity, and duration?
12 Net benefit and stopping rules Does a tested regimen have favorable demonstrated benefit–risk, and when must it be stopped?
13 Certainty and recommendation strength How do risk of bias, inconsistency, indirectness, imprecision, and publication bias affect confidence?
14 Implementation and updating What monitoring, equity, resources, feasibility, and updating process are needed?

6. Seven-Step Evidence-to-Recommendation Pathway

1. Define the population, nutrient, comparator, intended indication, and patient-important endpoints (PICO).
2. Characterize background exposure, nutritional status, clinically relevant demand, and priority.
3. Classify the claim on the functional–therapeutic continuum and distinguish nutritional from pharmacological administration.
4. Specify dose, form, route, achieved exposure, duration, and a prospective safety plan.
5. Appraise the direct clinical evidence, including null findings, harms, biological plausibility, and subgroup credibility.
6. Apply a recognized evidence-to-decision process, including effect magnitude, certainty, values, resources, equity, and feasibility.
7. Publish a clear recommendation or research-only conclusion with contraindications, monitoring, updating triggers, and evidence gaps.
The GRADE Evidence-to-Decision approach provides a suitable foundation for determining whether evidence supports a strong, conditional, or negative recommendation [8]. The I-OM-MGDF adds structured questions that may prevent omission of key nutrient-specific considerations, but it does not create an alternative evidence hierarchy.

7. Worked Application I: Vitamin D and Disease Prevention

Question: Does routine vitamin D supplementation prevent cancer or major cardiovascular disease among generally healthy middle-aged and older adults? VITAL assigned vitamin D3 2,000 IU/day or placebo and found no statistically significant reduction in either primary endpoint over the trial period [9]. Participants did not predominantly have severe deficiency. This trial provides important evidence about general supplementation in that population, but it does not replace clinical treatment of established osteomalacia or other accepted indications.
Demand/status: nutritional requirements and status may vary, but a subgroup benefit should not be assumed without credible interaction evidence. Continuum: VITAL tested preventive supplementation, not all possible deficiency treatment or high-dose interventions. Safety–benefit: a different dose cannot be recommended merely because the original result was null. Recommendation pathway: the 2024 Endocrine Society guideline examines disease prevention in people without established indications for testing or treatment, appropriately a different question from management of recognized deficiency [10].
Example output: For an average-risk generally healthy population, the cited evidence does not justify a universal claim that routine vitamin D3 at the trial dose prevents cancer or major cardiovascular events. Clinicians should independently address established deficiency-related indications, where relevant. Proposed higher biomarker targets or high-dose strategies require outcome-specific evidence and safety analysis.

8. Worked Application II: Vitamin C from Replacement to Pharmacological Exposure

Question A: Should vitamin C deficiency be corrected? Yes: prevention and treatment of scurvy is an established nutritional indication. Question B: Should nutritionally replete individuals take higher oral doses for a specified outcome? That requires outcome-specific trial evidence and characterization of marginal benefit and tolerability. Question C: Does intravenous high-dose vitamin C improve a defined clinical outcome in cancer? This is a pharmacological, disease-specific question, not answered solely by the nutritional necessity of ascorbate or oral supplement trials.
Padayatty and colleagues documented that intravenous dosing can achieve plasma concentrations unattainable by oral administration [6]. The National Cancer Institute summary describes research interest while highlighting that high-dose IV vitamin C may cause serious problems in patients with renal disease or G6PD deficiency, and may interfere with some clinical laboratory and glucose measurements [11]. Mechanistic differences justify specific trials, not substitution for established oncologic care.
I-OM-MGDF output: maintain separate guideline statements for nutritional adequacy, oral supplementation, and intravenous pharmacological ascorbate. For the latter, require clinically meaningful endpoints, validated screening for relevant contraindications, renal and metabolic risk assessment, exposure documentation, interaction review, and trial-appropriate monitoring. Absent sufficient evidence for a specified disease outcome, classify efficacy as unestablished or investigational rather than automatically favorable.

8.1. Biological Timing as a Worked Contrast: Periconceptional Folic Acid

Folic acid demonstrates a preventive intervention with a well-defined biological window: the US Preventive Services Task Force recommends 400–800 μg/day for persons who plan to or could become pregnant to reduce neural tube defects [14]. Exposure initiated too late cannot be expected to prevent developmental events that have already occurred. This example supports the framework’s explicit timing domain and illustrates a successful population-specific intervention without implying that increasingly high folic acid doses produce progressively larger benefits.

9. Counterexamples: Nutrients Can Cause Harm Beyond Adequacy

Vitamin E and beta-carotene trials demonstrate why exposure beyond nutritional sufficiency must not be presumed advantageous. In SELECT, vitamin E supplementation increased prostate cancer risk in the studied population [12]. In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, beta-carotene supplementation increased lung cancer incidence among male smokers [13]. These findings are not evidence that the nutrients are physiologically unimportant; they are evidence against those particular disease-prevention interventions and remind guideline developers that isolated supplementation may differ from food-associated exposure.
The NSBEP must operate symmetrically: it is a reason to investigate plausible benefit and to actively search for potential harm. Neither an observational association nor a favorable mechanistic pathway should override a well-conducted adverse-outcome trial.

10. Safety Architecture: What Constitutes a Justified Exposure Study?

Before selecting a high-dose or pharmacological exposure, investigators should specify: a biologically coherent indication; existing efficacy and toxicology evidence; anticipated exposure; selection and exclusion criteria; formulation and delivery route; organ-specific contraindications; prespecified adverse-event grading; stopping rules; treatment interactions; duration of surveillance; and processes for reporting delayed harms. Depending on study risk, independent oversight and staged dose escalation may be appropriate.
Safety boundaries should not be inferred from a single “safe dose.” A lowest-observed-adverse-effect level, a no-observed-adverse-effect level, a regulatory UL, an experimental MTD, and a regimen with demonstrated net clinical benefit answer different questions. Thresholds may vary across jurisdictions, endpoints, exposure durations, and patient groups. The dose with greatest established benefit is not necessarily the dose with minimal detectable toxicity, and the highest tolerated dose may be inferior to a lower dose.
The ethical principle for exploratory dosing is equipoise with proportional safeguards: sufficiently plausible benefit and sufficiently characterized risk to justify research. If evidence of efficacy is weak and harms are serious or uncertain, the appropriate response is to collect better preclinical or early-phase data rather than to recommend routine use.

10.1. Distinguishing Mild Toxicity, Serious Harm, and Uncertainty

Nutrient-specific safety assessments should record severity, likelihood, time to onset, duration, reversibility, and whether injury is detectable only by laboratory testing. A transient gastrointestinal effect and irreversible neuropathy are not comparable harms. For vitamin B6, EFSA identified peripheral neuropathy as the critical endpoint and established an adult tolerable upper intake level of 12 mg/day [5]. This example underscores the need to avoid treating a short symptom-free observation period as evidence of long-term safety.

10.2. A decision Rule for Exploring Exposures Beyond Nutritional Adequacy

A dose above the established requirement should be considered for formal research when (i) the proposed clinical endpoint is specified; (ii) mechanistic or preliminary human data support a plausible benefit; (iii) the toxicological evidence is adequate for the planned dose, population, route, and duration; (iv) monitoring and stopping rules are prospectively defined; and (v) the study can resolve a meaningful evidence gap. An intake below a known toxicity threshold is neither necessarily harmless nor an indication for empiric escalation. Evidence insufficient for routine use may nonetheless be sufficient to support a well-controlled trial. Conversely, serious or poorly characterized risk may make even an exploratory study unjustified.

10.3. Distinguishing Status, Dose, Route, and Clinical Outcome

Four variables should be reported separately: administered dose, total exposure from all sources, measured biological status or pharmacokinetic concentration, and patient-important clinical response. Observationally associated nutrient concentrations should not be labeled “optimal” without evidence that interventions targeting those concentrations improve outcomes. Comparisons of oral and intravenous ascorbate illustrate why pharmacokinetic separation merits hypothesis testing but cannot substitute for clinical efficacy trials [6,11].

11. Research, Guideline Governance, and Validation

Development of a guideline for guidelines requires more than a memorable conceptual structure. We propose four validation stages: (1) multidisciplinary content assessment including clinical nutrition, epidemiology, pharmacology, toxicology, statistics, patient representation, and guideline methodology; (2) pilot application to existing vitamin C, vitamin D, vitamin B6, iron, and folate recommendations; (3) assessment of inter-rater agreement, usability, redundancy, and missed decision-relevant evidence; and (4) prospective evaluation of whether use of the checklist improves transparency and recommendation quality without introducing systematic bias toward supplementation.
Potential failure modes include retrospective reinterpretation of negative studies, excessive testing of unvalidated biomarkers, treating proposed nutrient demand as demonstrated requirement, and conflating absence of measured toxicity with proof of safety. To mitigate these, guideline panels should prespecify the question, present evidence supporting and opposing each claim, disclose conflicts of interest, and retain external evidence-to-decision standards.
When translated into I-OM.ai educational resources or AI decision support, the framework should preserve explicit labels: established indication; evidence-supported conditional use; plausible but unproven hypothesis; and intervention with evidence of no net benefit or harm. The system should not turn the framework into a default instruction to increase supplement dosage.

11.1. Relationship to Prior Author Publications

The current contribution is a guideline-development integration rather than a first publication of nutrient prioritization or nutrient demand. In particular, the original four-level prioritization hierarchy should remain attributed to the June 2026 preprint [19], while this manuscript’s five-part use classification serves a different purpose: classifying intended claims rather than prescribing a replacement prioritization hierarchy. Earlier commentary on high-dose orthomolecular approaches [17] and a peer-reviewed vitamin D guideline review [18] motivate research questions but do not constitute validation of the newly proposed methodology.

11.2. Relationship to Established Reporting and Guideline Standards

The proposed checklist should be implemented alongside, rather than in place of, recognized methods. CONSORT 2025 provides updated standards for transparent randomized-trial reporting [15], SPIRIT 2025 addresses protocol completeness [16], and GRADE supports certainty judgments and evidence-to-decision processes [8]. Proposed nutrient-specific extensions should be tested for inter-rater reliability, added burden, and influence on guideline decisions before claiming methodological superiority.

12. Strengths and Limitations

The proposed framework offers an explicit connection between nutrient physiology, scope of the clinical question, dose and exposure, serious safety analysis, and formal guideline recommendations. Its four organizing principles may facilitate consistent consideration of areas that are sometimes separated across disciplines.
Limitations are substantial. This is not a systematic review. The principles have not been independently validated, operational variables may overlap, and a universal checklist cannot replace nutrient-specific science. Some of the methods described—pharmacokinetics, status stratification, harms monitoring, and effect modification—are already used in rigorous pharmaceutical and nutritional research. The novelty therefore lies in their proposed integration and systematic application, not in claims of their original discovery. Nutrient-specific evidence remains decisive: insufficient data on “optimal” status or higher dosing cannot be remedied by adopting a new doctrine.

13. Conclusions

Evidence-based micronutrient guidelines should ask more than the dose required to avert overt deficiency. They should determine what is known about insufficient status, demand variation, biological exposure, meaningful patient benefit, and adverse effects, and whether therapeutic applications have been adequately tested. Neither the RDA nor the UL answers every therapeutic question; neither is evidence that maximum subtoxic intake produces optimal health.
Building on the previously published Nutrient Prioritization and increased-demand concepts [19] and earlier nutrient-dosing work [17,18], the I-OM-MGDF integrates four complementary principles—Nutrient Demand, Nutrient Prioritization, Nutrient Safety–Benefit Exploration, and the Nutrient Functional–Therapeutic Continuum—and operationalizes them through fourteen guideline-development domains. Its central standard is symmetrical and falsifiable: credible hypotheses deserve appropriately controlled investigation, favorable and unfavorable results deserve equal weight, and routine recommendations require demonstrated favorable net benefit. The framework should be piloted and independently evaluated before claims of validated guideline status are made.

Declarations

Author Contributions

Richard Z. Cheng: conceptualization, proposed methodology, critical interpretation, manuscript development, and responsibility for the final scientific content.

Funding

No external funding was received for this work.

Institutional Review Board Statement

Not applicable; this article does not report new research involving human participants or animals.

Data Availability Statement

No original datasets were generated or analyzed.

Use of Artificial Intelligence

Generative AI tools (ChatGPT, OpenAI) assisted with literature organization, drafting, structural editing, and language revision. The author takes responsibility for reviewing, checking, and approving all scientific claims, interpretations, references, and the final manuscript.

Conflicts of Interest

The author declares no conflicts of interest.

References

  1. Heaney, R.P. Nutrients, endpoints, and the problem of proof. J. Nutr. 2008, 138(9), 1591–1595. [Google Scholar] [CrossRef] [PubMed]
  2. Heaney, R.P. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr. Rev. 2014, 72(1), 48–54. [Google Scholar] [CrossRef] [PubMed]
  3. Institute of Medicine. Dietary Reference Intakes: Applications in Dietary Assessment; National Academies Press: Washington, DC, 2000. [Google Scholar] [CrossRef] [PubMed]
  4. Ames, B.N. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc. Natl. Acad. Sci. USA 2006, 103(47), 17589–17594. [Google Scholar] [CrossRef] [PubMed]
  5. EFSA Panel on Nutrition; Novel Foods and Food Allergens (NDA). Scientific opinion on the tolerable upper intake level for vitamin B6. EFSA J. 2023, 21(5), e08006. [Google Scholar] [CrossRef] [PubMed]
  6. Padayatty, S.J.; Sun, H.; Wang, Y.; et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern Med. 2004, 140(7), 533–537. [Google Scholar] [CrossRef] [PubMed]
  7. Lappe, J.M.; Heaney, R.P. Why randomized controlled trials of calcium and vitamin D sometimes fail. Dermatoendocrinol 2012, 4(2), 95–100. [Google Scholar] [CrossRef] [PubMed]
  8. Alonso-Coello, P.; Oxman, A.D.; Moberg, J.; et al. GRADE Evidence to Decision frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016, 353, i2089. [Google Scholar] [CrossRef] [PubMed]
  9. Manson, J.E.; Cook, N.R.; Lee, I.M.; et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl. J. Med. 2019, 380(1), 33–44. [Google Scholar] [CrossRef] [PubMed]
  10. Demay, M.B.; Pittas, A.G.; Bikle, D.D.; et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2024, 109(8), 1907–1947. [Google Scholar] [CrossRef] [PubMed]
  11. National Cancer Institute. Intravenous Vitamin C (PDQ®)—Health Professional Version. Available online: https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq (accessed on 21 October 2026).
  12. Klein, E.A.; Thompson, I.M.; Tangen, C.M.; et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306(14), 1549–1556. [Google Scholar] [CrossRef] [PubMed]
  13. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl. J. Med. 1994, 330(15), 1029–1035. [CrossRef] [PubMed]
  14. US Preventive Services Task Force. Folic acid supplementation to prevent neural tube defects: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 2023, 330(5), 454–459. [Google Scholar] [CrossRef] [PubMed]
  15. Hopewell, S.; Chan, A.W.; Collins, G.S.; et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ 2025, 389, e081123. [Google Scholar] [CrossRef] [PubMed]
  16. Chan, A.W.; Boutron, I.; Hopewell, S.; et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ 2025, 389, e081477. [Google Scholar] [CrossRef] [PubMed]
  17. Cheng, R.Z. Key Differences Between Conventional Nutrition and Orthomolecular Nutrition: The Role of Dosing and Regulatory Challenges. Orthomol. Med. News Serv. 2024, 20(21). Available online: https://orthomolecular.org/resources/omns/v20n21.shtml.
  18. Grant, W.B.; Wimalawansa, S.J.; Pludowski, P.; Cheng, R.Z. Vitamin D: Evidence-Based Health Benefits and Recommendations for Population Guidelines. Nutrients 2025, 17(2), 277. [Google Scholar] [CrossRef] [PubMed]
  19. Cheng, R.Z. The IOM Nutrient Prioritization Principle: A Systems Framework for Nutritional Intervention. Prepr. Posted 2026. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.